129 related articles for article (PubMed ID: 38232337)
21. Current trials and new aspects in soft tissue sarcoma of adults.
Issels RD; Schlemmer M
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
23. Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in high-risk extremity/trunk soft-tissue sarcoma?
Chowdhary M; Chowdhary A; Sen N; Zaorsky NG; Patel KR; Wang D
Cancer; 2019 Nov; 125(21):3801-3809. PubMed ID: 31490546
[TBL] [Abstract][Full Text] [Related]
24. Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial.
Puri A; Gulia A; Hawaldar R; Ranganathan P; Badwe RA
Clin Orthop Relat Res; 2014 May; 472(5):1568-75. PubMed ID: 24249538
[TBL] [Abstract][Full Text] [Related]
25. Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas.
Squires MH; Ethun CG; Suarez-Kelly LP; Yu PY; Hughes TM; Shelby RD; Tran TB; Poultsides G; Charlson J; Gamblin TC; Tseng J; Roggin KK; Chouliaras K; Votanopoulos K; Krasnick BA; Fields RC; Pollock RE; Grignol V; Cardona K; Howard JH
J Surg Res; 2020 Jan; 245():577-586. PubMed ID: 31494391
[TBL] [Abstract][Full Text] [Related]
26. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.
Gronchi A; Verderio P; De Paoli A; Ferraro A; Tendero O; Majò J; Martin J; Comandone A; Grignani G; Pizzamiglio S; Quagliuolo V; Picci P; Frustaci S; Dei Tos AP; Palassini E; Stacchiotti S; Ferrari S; Fiore M; Casali PG
Ann Oncol; 2013 Mar; 24(3):817-23. PubMed ID: 23110811
[TBL] [Abstract][Full Text] [Related]
27. Preoperative radiotherapy with concomitant chemotherapy in extremity soft tissue sarcomas: long-term results of a single center.
Yilmaz U; Kamer S; Kaya H; Sabah D; Sanli UA; Tamsel I; Yaman B; Akalin T; Anacak Y
Strahlenther Onkol; 2023 Jun; 199(6):585-594. PubMed ID: 36725697
[TBL] [Abstract][Full Text] [Related]
28. MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.
Martin-Broto J; Gutierrez AM; Ramos RF; Lopez-Guerrero JA; Ferrari S; Stacchiotti S; Picci P; Calabuig S; Collini P; Gambarotti M; Bague S; Dei Tos AP; Palassini E; Luna P; Cruz J; Cubedo R; Martinez-Trufero J; Poveda A; Casali PG; Fernandez-Serra A; Lopez-Pousa A; Gronchi A
Mol Cancer Ther; 2014 Jan; 13(1):249-59. PubMed ID: 24145283
[TBL] [Abstract][Full Text] [Related]
29. Influence of age and subtype in outcome of operable liposarcoma.
Greto D; Saieva C; Loi M; Terziani F; Visani L; Garlatti P; Lo Russo M; Muntoni C; Becherini C; Topulli J; Campanacci D; Beltrami G; Scoccianti G; Muratori F; Bonomo P; Desideri I; Francolini G; Livi L
Radiol Med; 2019 Apr; 124(4):290-300. PubMed ID: 30421387
[TBL] [Abstract][Full Text] [Related]
30. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.
Eilber FC; Eilber FR; Eckardt J; Rosen G; Riedel E; Maki RG; Brennan MF; Singer S
Ann Surg; 2004 Oct; 240(4):686-95; discussion 695-7. PubMed ID: 15383796
[TBL] [Abstract][Full Text] [Related]
31. Nuclear expression of DDIT3 distinguishes high-grade myxoid liposarcoma from other round cell sarcomas.
Baranov E; Black MA; Fletcher CDM; Charville GW; Hornick JL
Mod Pathol; 2021 Jul; 34(7):1367-1372. PubMed ID: 33731886
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD; von Mehren M; Jones RL; Hensley ML; Schuetze SM; Staddon A; Milhem M; Elias A; Ganjoo K; Tawbi H; Van Tine BA; Spira A; Dean A; Khokhar NZ; Park YC; Knoblauch RE; Parekh TV; Maki RG; Patel SR
J Clin Oncol; 2016 Mar; 34(8):786-93. PubMed ID: 26371143
[TBL] [Abstract][Full Text] [Related]
33. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas.
Chung PW; Deheshi BM; Ferguson PC; Wunder JS; Griffin AM; Catton CN; Bell RS; White LM; Kandel RA; O'Sullivan B
Cancer; 2009 Jul; 115(14):3254-61. PubMed ID: 19472403
[TBL] [Abstract][Full Text] [Related]
34. Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis.
Chaigneau L; Jary M; Nerich V; Hervieu A; Aubry S; Charon Barra C; Meynard G; Neumann F; Kalbacher E; Isambert N
Oncology; 2022; 100(12):633-644. PubMed ID: 36283345
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant
Tempero MA; Pelzer U; O'Reilly EM; Winter J; Oh DY; Li CP; Tortora G; Chang HM; Lopez CD; Bekaii-Saab T; Ko AH; Santoro A; Park JO; Noel MS; Frassineti GL; Shan YS; Dean A; Riess H; Van Cutsem E; Berlin J; Philip P; Moore M; Goldstein D; Tabernero J; Li M; Ferrara S; Le Bruchec Y; Zhang G; Lu B; Biankin AV; Reni M;
J Clin Oncol; 2023 Apr; 41(11):2007-2019. PubMed ID: 36521097
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial.
Sanfilippo R; Hindi N; Cruz Jurado J; Blay JY; Lopez-Pousa A; Italiano A; Alvarez R; Gutierrez A; Rincón-Perez I; Sangalli C; Pérez Aguiar JL; Romero J; Morosi C; Sunyach MP; Fabbroni C; Romagosa C; Ranchere-Vince D; Dei Tos AP; Casali PG; Martin-Broto J; Gronchi A
JAMA Oncol; 2023 May; 9(5):656-663. PubMed ID: 36995731
[TBL] [Abstract][Full Text] [Related]
37. Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall: Results of a Single-Arm Prospective Clinical Trial.
Koseła-Paterczyk H; Spałek M; Borkowska A; Teterycz P; Wągrodzki M; Szumera-Ciećkiewicz A; Morysiński T; Castaneda-Wysocka P; Cieszanowski A; Zdzienicki M; Goryń T; Rutkowski P
J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32752185
[TBL] [Abstract][Full Text] [Related]
38. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
[TBL] [Abstract][Full Text] [Related]
39. Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.
Martin-Broto J; Pousa AL; de Las Peñas R; García Del Muro X; Gutierrez A; Martinez-Trufero J; Cruz J; Alvarez R; Cubedo R; Redondo A; Maurel J; Carrasco JA; López-Martin JA; Sala Á; Meana JA; Ramos R; Martinez-Serra J; Lopez-Guerrero JA; Sevilla I; Balaña C; Vaz Á; De Juan A; Alemany R; Poveda A
J Clin Oncol; 2016 Jul; 34(19):2294-302. PubMed ID: 27185843
[TBL] [Abstract][Full Text] [Related]
40. First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.
Stacchiotti S; Van der Graaf WTA; Sanfilippo RG; Marreaud SI; Van Houdt WJ; Judson IR; Gronchi A; Gelderblom H; Litiere S; Kasper B
Cancer; 2022 Aug; 128(15):2932-2938. PubMed ID: 35561319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
